Rialto Wealth Management’s Acadia Pharmaceuticals ACAD Stock Holding History
Bought
Maintained
Sold
Other funds holding ACAD
BBA
Rialto Wealth Management's ACAD Position: Q3 2026 in Review
Rialto Wealth Management increased its Acadia Pharmaceuticals (ACAD) stake by 50% in Q3 2026, buying an estimated $134 and bringing the position to 15 shares worth $303. The position accounts for ﹤0.01% of the portfolio, ranked #1844.
Rialto Wealth Management first reported a position in ACAD in Q2 2025 and has held it in 6 quarters since. The position peaked at $321 in Q4 2025. 351 funds tracked by Wall St. Rank hold ACAD as of Q3 2026.
- Rialto Wealth Management held 15 shares of Acadia Pharmaceuticals worth $303 as of Q3 2026.
- Rialto Wealth Management bought 5 Acadia Pharmaceuticals shares in Q3 2026, an estimated $134.
- Acadia Pharmaceuticals made up ﹤0.01% of Rialto Wealth Management's portfolio in Q3 2026, its #1844 holding.
- Rialto Wealth Management first reported a position in Acadia Pharmaceuticals in Q2 2025 and has held it in 6 quarters since.
- Rialto Wealth Management's Acadia Pharmaceuticals position peaked at $321 in Q4 2025.
- 351 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2026.
Based on Rialto Wealth Management's 13F filing for Q3 2026, filed 16 Nov 2026.